A renaissance in targeting the PI3K/AKT/mTOR pathway
Conduit S, Vasan N, Brown J, Perry M, Vanhaesebroeck
Nature Reviews Drug Discovery,Jul 2026,https://doi.org/10.1038/s41573-026-01388-5
Quick read
The PI3K/AKT/mTOR pathway is an important drug target because it plays central roles in cancer, immune regulation, and genetic disease. Although efforts to develop therapies have been limited by toxicity and drug resistance, new biological insights and pharmaceutical strategies are renewing momentum in targeting this pathway.
A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance
Karunaraj P, Scheele R, Wells ML, Rathod R, Abrahamson S, Taylor LC, Gokulu IS, Chowdhury L, Kazmi A, Song W, Hornbeck P, Li J, Glasgow A, Vasan N
Nature Communications,Dec 2025,https://doi.org/10.1038/s41467-026-70060-8
Quick read
SHP2 is a key regulator of RTK-driven RAS/MAPK signaling, but SHP2 inhibitors have shown limited clinical benefit and the causes of primary resistance have remained unclear. This study identifies phosphorylation of SHP2 at Y62 as a recurrent resistance mechanism that locks SHP2 in an active state, drives MAPK signaling, and reveals a drug target distinct from wild-type SHP2.
A New VISTA in Intracellular Checkpoint Signaling in Triple-Negative Breast Cancer
Tao JJ, Vasan N
Cancer Research,Sep 2025,10.1158/0008-5472.CAN-25-2286
Quick read
VISTA can suppress tumor growth in a subset of VISTA-expressing triple-negative breast cancers through a cell-intrinsic mechanism independent of the immune system. A four-amino-acid NPGF motif within VISTA recruits NUMB to endosomes, disrupting growth-factor receptor trafficking and revealing an unexpected role for VISTA in directly regulating cancer cell signaling.
Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer
Ulene SR, Wang S, Cook JR, McAuley F, Wooster ME, Faheem KF, Varoli A, McGuinness JE, Vasan N, Trivedi MS, Crew KD, Harden E, Law C, Hershman DL, Accordino MK
Breast Cancer Research and Treatment,Aug 2025,10.1007/s10549-025-07745-z
Quick read
Chemotherapy and supportive medications such as dexamethasone can disrupt glucose regulation in patients with breast cancer. Continuous glucose monitoring revealed that all patients with early-stage breast cancer experienced hyperglycemia during treatment, but the duration and severity varied dramatically by baseline glucose status, with prediabetes or diabetes associated with substantially more time spent hyperglycemic.
Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations
Chaki M, Benrashid M, Puri S, Sivakumar S, Sokol ES, Briceno JM, Vasan N
Breast Cancer Research,Jul 2025,10.1186/s13058-025-02055-0
Quick read
Blood-based NGS reliably detected clinically relevant PIK3CA, AKT1, and PTEN short variants in breast cancer when ctDNA tumor fraction was ≥1%, showing strong agreement with tissue-based sequencing. At very low tumor fractions and for copy-number alterations, sensitivity declined substantially, supporting tissue-based testing when liquid biopsy results are negative or inconclusive.
Clinicogenomic landscape and function of PIK3CA, AKT1, and PTEN mutations in breast cancer
Tao JJ, Sisoudiya SD, Tukachinsky H, Schrock A, Sivakumar S, Sokol ES, Vasan N
medRxiv (Preprint),Jun 2025,10.1101/2025.06.18.25329632
Quick read
Profiling more than 51,000 breast tumors revealed distinct patterns of PIK3CA, AKT1, and PTEN alterations, including differences in mutation frequency, co-occurring genomic changes, and patient ancestry. Functional characterization of rare variants further expanded the spectrum of potentially meaningful alterations within the AKT pathway beyond the mutations that are already well established.
LIN28B-mediated PI3K/AKT pathway activation promotes metastasis in colorectal cancer models
Shin AE, Sugiura K, Kariuki SW, Cohen DA, Flashner SP, Klein-Szanto AJ, Nishiwaki N, De D, Vasan N, Gabre JT, Lengner CJ, Sims PA, Rustgi AK
The Journal of Clinical Investigation,Jan 2025,10.1172/JCI186035
Quick read
LIN28B activates PI3K/AKT signaling to promote an aggressive, metastatic state in colorectal cancer. Blocking this signaling axis reversed key LIN28B-driven behaviors across experimental models, revealing PI3K/AKT as a central mechanism underlying LIN28B-mediated metastasis.
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations
Yasin F, Sokol E, Vasan N, Pavlick DC, Huang RSP, Pelletier M, Levy MA, Pusztai L, Lacy J, Zhang JY, Ross JS, Cecchini M
The Oncologist,Dec 2024,10.1093/oncolo/oyae259
Quick read
Multi-hit PIK3CA mutations occur in a distinct subset of advanced colorectal cancers and are associated with a unique genomic profile, including frequent co-occurring RAS/RAF alterations and enrichment for high tumor mutational burden and microsatellite instability. These tumors may have enhanced sensitivity to PI3K inhibition, highlighting opportunities for PI3K-targeted and rational combination therapies.
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study
Basin MF, Miguel CM, Jacob JM, Goldberg H, Grivas P, Spiess PE, Necchi A, Kamat AM, Pavlick DC, Huang RSP, Lin DI, Danziger N, Sokol ES, Sivakumar S, Graf R, Cheng L, Vasan N, Ross J, Basnet A, Bratslavsky G
Targeted Oncology,Nov 2024,10.1007/s11523-024-01100-w
Quick read
Multi-hit PIK3CA mutations define a rare but distinct subset of advanced prostate cancers with greater genomic complexity, higher tumor mutational burden, and increased microsatellite instability compared with PIK3CA wild-type tumors. These findings suggest that PIK3CA alterations could help identify patients who may benefit from PI3K-targeted therapies and potentially immune checkpoint inhibition.
Therapeutic potential of inhibiting the PI3Kγ complex for leukemia
Karvonen H, Vasan N
Cell Chemical Biology,Jul 2024,10.1016/j.chembiol.2024.06.009
Quick read
IPI3Kγ has emerged as an unexpected cancer-cell-intrinsic dependency in acute leukemia, with leukemia cells relying on noncanonical PI3Kγ signaling for survival and growth beyond its traditional functions in immune cells. Selectively inhibiting the PI3Kγ complex could therefore expose a therapeutically actionable vulnerability and provide a new targeted treatment strategy for subsets of acute leukemia.